arrow_back Back to App

HALT Fentanyl Act: Combating Fentanyl and Streamlining Research

This act aims to combat illegal fentanyl trafficking by classifying fentanyl-related substances as dangerous drugs. Simultaneously, it introduces changes to expedite and simplify scientific research on these substances, potentially leading to new treatments and addiction solutions. For citizens, this means enhanced safety through reduced access to illegal substances and hope for faster medical advancements in addiction treatment.
Key points
All chemically similar fentanyl substances are now treated like fentanyl, making it easier to prosecute traffickers.
Procedures for scientists researching fentanyl and similar substances have been simplified to accelerate drug development.
Researchers can now conduct studies at multiple sites under a single registration, reducing bureaucracy.
Provisions allow for the continuation of research on substances newly added to the list of dangerous drugs, without immediate interruption.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_S_3336
Sponsor: Sen. Cassidy, Bill [R-LA]
Process start date: 2021-12-08
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

HALT Fentanyl Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_S_3336.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2021-12-08.

What are the main provisions?

Key points include:

  • All chemically similar fentanyl substances are now treated like fentanyl, making it easier to prosecute traffickers.
  • Procedures for scientists researching fentanyl and similar substances have been simplified to accelerate drug development.
  • Researchers can now conduct studies at multiple sites under a single registration, reducing bureaucracy.
  • Provisions allow for the continuation of research on substances newly added to the list of dangerous drugs, without immediate interruption.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Cassidy, Bill [R-LA].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-29.

CATEGORIES

Security Health Courts and Law